Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida. more
Time Frame | CPRX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -0.51% | -2.12% | -3% |
1-Month Return | 0.57% | -3.42% | -0.73% |
3-Month Return | 2.31% | -11.13% | 2.87% |
6-Month Return | 40.12% | -5.74% | 7.17% |
1-Year Return | 48.74% | 3.97% | 25.31% |
3-Year Return | 207.37% | 1.05% | 28.38% |
5-Year Return | 459.74% | 34.37% | 81.89% |
10-Year Return | 609% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 102.31M | 119.07M | 140.83M | 214.20M | 398.20M | [{"date":"2019-12-31","value":25.69,"profit":true},{"date":"2020-12-31","value":29.9,"profit":true},{"date":"2021-12-31","value":35.37,"profit":true},{"date":"2022-12-31","value":53.79,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 14.76M | 17.04M | 21.88M | 34.39M | 84.53M | [{"date":"2019-12-31","value":17.46,"profit":true},{"date":"2020-12-31","value":20.16,"profit":true},{"date":"2021-12-31","value":25.89,"profit":true},{"date":"2022-12-31","value":40.69,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 87.55M | 102.03M | 118.95M | 179.81M | 313.67M | [{"date":"2019-12-31","value":27.91,"profit":true},{"date":"2020-12-31","value":32.53,"profit":true},{"date":"2021-12-31","value":37.92,"profit":true},{"date":"2022-12-31","value":57.32,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 85.57% | 85.69% | 84.46% | 83.94% | 78.77% | [{"date":"2019-12-31","value":99.86,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":98.57,"profit":true},{"date":"2022-12-31","value":97.96,"profit":true},{"date":"2023-12-31","value":91.93,"profit":true}] |
Operating Expenses | 55.72M | 60.73M | 66.56M | 77.97M | 259.43M | [{"date":"2019-12-31","value":21.48,"profit":true},{"date":"2020-12-31","value":23.41,"profit":true},{"date":"2021-12-31","value":25.66,"profit":true},{"date":"2022-12-31","value":30.06,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 31.82M | 41.30M | 52.38M | 101.84M | 86.81M | [{"date":"2019-12-31","value":31.25,"profit":true},{"date":"2020-12-31","value":40.56,"profit":true},{"date":"2021-12-31","value":51.44,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":85.25,"profit":true}] |
Total Non-Operating Income/Expense | 3.17M | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | 33.41M | 41.89M | 52.67M | 104.72M | 94.51M | [{"date":"2019-12-31","value":31.9,"profit":true},{"date":"2020-12-31","value":40,"profit":true},{"date":"2021-12-31","value":50.29,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":90.25,"profit":true}] |
Income Taxes | 1.53M | (33.09M) | 13.19M | 21.64M | 23.10M | [{"date":"2019-12-31","value":6.64,"profit":true},{"date":"2020-12-31","value":-143.25,"profit":false},{"date":"2021-12-31","value":57.08,"profit":true},{"date":"2022-12-31","value":93.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | 31.88M | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | 31.88M | 74.98M | 39.48M | 83.08M | 62.04M | [{"date":"2019-12-31","value":38.37,"profit":true},{"date":"2020-12-31","value":90.26,"profit":true},{"date":"2021-12-31","value":47.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":74.67,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 31.88M | 74.98M | 39.48M | 83.08M | 71.41M | [{"date":"2019-12-31","value":38.37,"profit":true},{"date":"2020-12-31","value":90.26,"profit":true},{"date":"2021-12-31","value":47.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":85.95,"profit":true}] |
EPS (Diluted) | 0.30 | 0.41 | 0.37 | 0.74 | 0.81 | [{"date":"2019-12-31","value":37.04,"profit":true},{"date":"2020-12-31","value":50.62,"profit":true},{"date":"2021-12-31","value":45.68,"profit":true},{"date":"2022-12-31","value":91.36,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
CPRX | |
---|---|
Cash Ratio | 4.20 |
Current Ratio | 5.11 |
Quick Ratio | 4.92 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CPRX | |
---|---|
ROA (LTM) | 18.35% |
ROE (LTM) | 28.29% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CPRX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.14 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.86 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CPRX | |
---|---|
Trailing PE | 18.09 |
Forward PE | 11.09 |
P/S (TTM) | 5.53 |
P/B | 3.98 |
Price/FCF | 35 |
EV/R | 4.76 |
EV/Ebitda | 10.37 |
PEG | NM |
Catalyst Pharmaceuticals Inc (CPRX) share price today is $21.27
Yes, Indians can buy shares of Catalyst Pharmaceuticals Inc (CPRX) on Vested. To buy Catalyst Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CPRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Catalyst Pharmaceuticals Inc (CPRX) via the Vested app. You can start investing in Catalyst Pharmaceuticals Inc (CPRX) with a minimum investment of $1.
You can invest in shares of Catalyst Pharmaceuticals Inc (CPRX) via Vested in three simple steps:
The 52-week high price of Catalyst Pharmaceuticals Inc (CPRX) is $24.27. The 52-week low price of Catalyst Pharmaceuticals Inc (CPRX) is $13.12.
The price-to-earnings (P/E) ratio of Catalyst Pharmaceuticals Inc (CPRX) is 18.0932
The price-to-book (P/B) ratio of Catalyst Pharmaceuticals Inc (CPRX) is 3.98
The dividend yield of Catalyst Pharmaceuticals Inc (CPRX) is 0.00%
The market capitalization of Catalyst Pharmaceuticals Inc (CPRX) is $2.55B
The stock symbol (or ticker) of Catalyst Pharmaceuticals Inc is CPRX